articles nature publishing group Background More than 40% of treated hypertensives in the United States do not have their blood pressure under control. This is partly owing to non-persistence with prescribed medication, which occurs within 1 year in 32-53% of newly treated patients. Knowledge of factors related to non-persistence is limited, partly because previous studies have being conducted mostly in elderly patients enrolled in a single health insurance.
Long-term control of elevated arterial pressure results in large reductions in morbidity and mortality attributable to hypertension. 1 However, only 57% of known hypertensive patients receiving pharmacologic treatment in the United States have their blood pressure controlled. 2 It is estimated that 15% of all cases of acute myocardial infarction 3 and 32% of all strokes 4 among subjects treated for hypertension can be attributed to uncontrolled blood pressure. Failure by patients to use medications as prescribed is considered a major contributor to poor control of hypertension and lessens the effectiveness of antihypertensive drugs in preventing stroke, coronary heart disease, and chronic kidney disease. 5 In fact, simulation studies suggest that improving compliance with existing antihypertensive medication could be more beneficial than using an ideal antihypertensive drug, i.e., a drug that makes the quality-adjusted life expectancy of a hypertensive person similar to that of a non-hypertensive. 6 Non-adherence to prescribed antihypertensive medication is highly prevalent. Patients may either modify or miss medication doses in the context of ongoing use (non-compliance) or may prematurely discontinue therapy completely (non-persistence). 7 Pharmacy claims data have been frequently used to estimate compliance as the ratio of total days of medication supplied to total days in a period of time (medication possession ratio). 7 In a recent study among new hypertensive patients enrolled in a single health insurance plan, Grant et al. found a 35% cumulative non-compliance (medication possession ratio <80%) over an average follow-up of 40 months. 8 Similarly, in a large study among patients from the Department of Veteran's Affairs compliance rates ranged from 78 to 84% over 12 months. 9 Pharmacy claims databases have also been used to identify patients who stop filling out their prescription medication for a predefined period of time (non-persistent). Recent studies using this approach have shown that 32-53% of newly treated hypertensives stop using their medication by the end of the first year of treatment. 10, 11 Several factors have been associated with antihypertensive treatment non-compliance and non-persistence. However, results from previous studies of non-adherence are of limited generalizability because they have been conducted mostly among middle-aged and elderly patients enrolled in a single health insurance. 9, 10, 12, 13 Also, these studies have provided little information on the effects of enabling factors such as health insurance, income, and use of health services, since all participants were insured and received total or partial reimbursement articles Persistence With Antihypertensive Therapy for prescribed medications. 9, 12, 14 Moreover, findings from previous studies 12, 13 may not apply to current practice, since the pattern of medication prescription and use has likely changed during the last decade as a consequence of increasing awareness of the benefits of blood pressure reduction, new practice guidelines, and availability of newer drugs with less undesirable side effects. 15, 16 This study used data from the National Health and Nutrition Examination Surveys (NHANES) to evaluate the role of factors that describe the propensity of patients to comply with treatment recommendations (predisposing factors); factors that comprise the resources available to help patients in obtaining health care and medications (enabling factors); and factors that reflect the patients' requirements for care and medication (need characteristics). 17 
Methods
Analyses in this article are based on data from NHANES III (1988) (1989) (1990) (1991) (1992) (1993) (1994) , 18 NHANES 1999 , and NHANES 2001 -2002 . 19 NHANES III was conducted in two phases, from 1988 to1991 and from 1991 to 1994. The most recent NHANES have a similar design but are conducted in yearly waves. Also, a unique set of weights is available for combining the data from NHANES 1999-2000 and 2001-2002. The sample for NHANES is selected through a complex multistage design based on primary sampling units (counties), household segments within the counties, and finally, sampled persons from selected households. This design is aimed to obtain a representative sample of the civilian non-institutionalized population of the United States. African Americans, Mexican Americans, people of age 12-19 and >60-years, low-income whites, and pregnant women are oversampled to obtain precise estimates in these groups. NHANES participants provided informed consent and the data collection procedures are approved by the Centers for Disease Control and Prevention Institutional Review Board as ensuring confidentiality.
This analysis includes NHANES participants who reported they had been diagnosed with hypertension and advised by their physicians to use antihypertensive medication (n = 6,733). Trained NHANES interviewers verified the medications being used during the 30 days prior to the survey date by direct inspection of medication containers. Individuals who did not use antihypertensive medication during that period were classified as non-persistent. A group of 571 participants who were not taking antihypertensive medication and had normal blood pressure during the physical exam (systolic blood pressure <140 and diastolic blood pressure <90 mm Hg) was excluded. These participants were likely normotensives or hypertensives who had their blood pressure controlled by non-pharmacologic therapy. They would have been falsely classified as cases of non-persistence, and their inclusion would have biased the observed associations towards the null. Pregnant women (n = 14) and subjects without medication use data were also excluded (n = 48). The analysis was aimed at identifying the independent effect of predisposing factors (age, gender, ethnicity, education, marital status, language, alcohol intake, and smoking), enabling factors (average family annual income, having health insurance, and visits to the doctor during the last year), and need characteristics (body mass index, self-reported health status, and coexisting chronic disease). People with a history of diseases that require regular and persistent use of medications were classified as having a chronic disease. This included people with a history of arthritis, stroke, emphysema, cancer, asthma, bronchitis, diabetes, or acute myocardial infarction.
All analyses were statistically weighted to maintain the representativeness of the sample for the US population, to avoid selection bias, and to correctly estimate the precision of regression coefficients. NHANES mobile examination center-examined sample weight values were used to adjust for the differential probabilities of selection and non-response in the survey sample. 19, 20 A new set of analytical weights was calculated and used in the analysis to account for the fact that data came from two independent surveys (NHANES III and NHANES 1999-2000 plus NHANES 2001-2002). The new set of sampling weights was calculated as a weighted average of the original weights, following the recommendation of Korn and Graubard. 21 This approach yields unbiased and efficient estimation of population parameters. Although sampling weights account for nonparticipation, they do not account for the exclusion of subjects that results from missing data on one or more variables included in the analysis. If subjects with missing data are excluded, the sum of the weights for the remaining subjects will not equal the population size and selection bias could occur. 22 To avoid this bias, multivariate imputation by chained equations was used to fill out missing values and to generate 10 imputed data sets. 23 Each completed data set was analyzed independently and the parameters of interest were averaged across the 10 copies, using Rubin's formula, 24 to obtain a single estimate. Multiple logistic regression with sampling weights was used to estimate the independent effect of each factor on non-persistence. The first imputed data set was used for model building and variable selection and the resulting model was applied to the remaining data sets before averaging the estimates. 22 The excess fraction (attributable risk), i.e., the proportion of non-persistent cases in the population that could be reasonably associated to each factor, was used to summarize the impact of enabling factors on nonpersistence. The excess fraction was calculated as the proportion of exposed cases times (odds ratio (OR)−1/OR). 25 All analyses were conducted adjusting for the complex survey design using were men, 76% were White, and 33% had a less than high school education ( Table 1) . Smoking and alcohol intake were considerably higher in non-persistent patients. Lack of health insurance and not visiting the doctor during the last year were also higher among subjects who were not taking antihypertensive medications ( Table 2) . Also, a significant fraction (66%) reported suffering from at least one chronic disease with non-persistence cases being more likely to have a chronic disease.
The crude analysis showed that non-persistence increased dramatically with younger age and with subjects <30 being articles Persistence With Antihypertensive Therapy more than 10 times more likely to be non-persistent than those ≥50 years old ( Table 3) . Participants ≥50 years old were used as the reference group because the prevalence of non-persistence was homogeneous and the lowest in this age group. Men, African Americans, Hispanics, and those who were divorced were significantly more likely to be non-persistent. Also, nonpersistence prevalence was significantly higher among smokers and individuals who had ≥2 alcohol drinks/day. Individuals with average family income <$55,000/year were twice as likely to be non-persistent (Table 4) . However, the larger crude increases in the frequency of non-persistence occurred in people who did not visit a physician during the last year (OR: 11.86; P < 0.001) and those without health insurance (OR: 3.15; P < 0.001). On the contrary, individuals who were suffering from some form of chronic disease were significantly less likely to be non-persistent (OR: 0.59; P = 0.006).
The results from the multivariate analysis showed that age, gender, and race were the only predisposing factors independently associated to non-persistence with antihypertensive medication. After adjustment for other risk factors, non-persistence increased about 2.5 times in people 40-49 and 30-39 years old (P < 0.001) and over 12 times in those <30 years old (P < 0.001), as compared to patients ≥50 years old (Table 5) . Also, non-persistence was 31% more likely in men than in women (P = 0.011) and 43% more likely in Hispanics than in other ethnic groups (P = 0.027). All studied enabling factors were independently and significantly associated with non-persistence ( Table 5) . Low-income patients were 1.96 times more likely to be non-persistent than those with a family average income ≥$50,000/year (P < 0.001). Similarly, non-persistence was 1.88 times more frequent among patients without health insurance (P = 0.002). However, visiting the doctor during the last year was the enabling factor with the strongest effect on non-persistence. Patients who did not seek medical attention during the last year were over 10 times more likely to be non-persistent than those who made at least one medical visit (P < 0.001). After adjustment for other factors, none of the need factors studied (body mass index, self-reported health status, and coexisting chronic disease) was significantly associated to non-persistence. On the other hand, the prevalence of non-persistence decreased by 27% between 1988-1994 and 1999-2002 (P = 0.019).
The fraction of cases of non-persistence that could theoretically be prevented by eliminating the exposure (excess fraction) was discussion Despite significant advances in detection, treatment, and control of high blood pressure, 2 essential hypertension remains the second major contributor to the current burden of morbidity and mortality in developed countries and developing countries with low mortality. 26 Poor medication-taking behavior is a major determinant of uncontrolled blood pressure, a condition that occurs in over 40% of treated hypertensives in the United States. 2 This study shows that 12.5% of hypertensive patients advised to take blood pressure lowering medication are not taking it, even though they still have elevated blood pressure. Age was the stronger predictor of non-persistence in this study, with subjects <30 being 12 times more likely to be non-persistent than those ≥50 years old, independent of other risk factors. The observed age effect was of the same direction but stronger than the effect reported in previous studies. 10, 27 The stronger age effect observed in this study is probably a consequence of including subjects from a wider age range than those included in previous studies. 10, 27 Prevalence of non-persistence was 31% higher in men than in women. Previous studies have shown that non-persistence is 8-12% more frequent among men but have failed to adjust for other predisposing and enabling factors. 10, 27 Although crude non-persistence prevalence was significantly higher in African Americans and Hispanics, the adjusted analysis showed no relative increase in African Americans and a significant 43% increase in Hispanics, as compared to other racial groups. An effect of race on treatment persistence has not been previously reported, but several studies have shown an increased risk of non-compliance among African Americans, as compared to whites. 9, 13, 14 Unfortunately, those studies have included few or no Hispanics and have not taken into account important confounders. An increased non-persistence in Hispanics could be partly explained by communication difficulties owing to linguistic barriers and poor understanding between patient and physician. Unfortunately, no data on the language spoken by the treating physician were available.
Although financial problems are commonly cited as a barrier to hypertensive care, 28 most studies of antihypertensive treatment adherence have been conducted in insured populations with total or partial reimbursement for prescribed medications, limiting the opportunity to assess the role of enabling factors such as income, health insurance, and use of health services. 9, 10, 13, 27 Results from this analysis indicate that patient with an average family income below $50,000/year were almost two times more likely to be non-persistent than those with higher income. Low income has been associated to lower frequency of hypertension screening but did not seem to influence pharmacologic treatment or patient follow-up. 28 Lack of health insurance was associated with an 88% increase in the risk of non-persistence in the present study. This finding is consistent with poorer follow-up of treated hypertensives without health insurance reported in a previous study. 28 An important finding of the present study was that patients who did not visit their doctor during the year preceding the interview were 10 times more likely to be non-persistent than those who made at least one medical visit. In a large population study, Perreault et al. found that a greater number of medical visits had no significant effect, whereas hospitalization had a significant positive impact on persistence. 10 Also, Caro et al. has reported significantly increased persistence in hypertensive patients who visited the doctor five or more times during the last year. 27 Consistent results have also been observed in studies of compliance. 13, 14 These results suggest that factors that help patients to obtain medication and health care could significantly improve treatment persistence.
Several limitations must be considered in interpreting these results. First, this analysis is based on a cross-sectional sample that includes only those hypertensive patients who survived up to the time of the interview. Since survival should be higher for patients who remain under treatment, the results of this analysis may be different from those from a cohort study. However, findings from this analysis are still useful to identify potential determinants of persistence and high-risk groups. Second, there was no way to verify whether the doctor had actually prescribed antihypertensive medication. However, Klungel et al. 29 compared self-reported antihypertensive drug use and pharmacy records and found that the accuracy of self-report was considerably high (sensitivity of 94.2% and specificity of 96.3%). Therefore, this source of error should have a negligible impact on the results of the present study. Third, non-persistent patients in this study are a mix of those who never started treatment and those who stopped taking their medication for at least 1 month. Whether the observed associations are different for one group and the other cannot be ascertained with the data at hand. Finally, the type of antihypertensive medication prescribed to non-persistent patients is not known. This may be of relevance, since the type of antihypertensive drug influences persistence and is related to factors such as age, gender, and comorbidities. 10, 30 To my knowledge, this study is the first of its kind to measure simultaneously the independent effect of patient's predisposing, enabling, and need characteristics on persistence with antihypertensive medication. The main strength of this study is the use of data from NHANES. Since NHANES provide nationally representative samples, the findings from this analysis are unlikely affected by selection bias and can be extrapolated to the US population. This study, in particular, overcomes the limitations of previous studies that mostly comprised elderly people enrolled in a health insurance plan, with less than ideal representation of ethnic minorities. Another strength of the present analysis study was the availability of high quality data for the definition of the target population and the ascertainment of persistence status. Specifically, hypertensive status was determined by interview and blood pressure measurements, and trained interviewers verified the medications being used articles Persistence With Antihypertensive Therapy by direct inspection of medication containers. Finally, I was able to account for the effect of multiple characteristics that influence the use of antihypertensive medication, beyond those regularly available in pharmacy claims databases.
In summary, non-persistence with antihypertensive medication increased significantly with young age, in men, and among Hispanics. Non-persistence was also considerably increased in populations with financial barriers to the availability of health care. In fact, low income, having no health insurance, and not visiting the doctor during the last year accounted for more than 50% of the cases of non-persistence. Policies that improve access to health care and patient follow-up may be of great importance in maintaining long-term persistence with antihypertensive medication.
